Alzheimer's Disease
Conditions
Interventions
Surgical group:Deep Cervical Lymphaticovenous Anastomosis
Sponsors
Department of Neurosurgery, First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Meets the core clinical diagnostic criteria for probable Alzheimer's disease (AD) dementia as defined in the 2011 NIA-AA version (core criteria: a. insidious onset and progressive worsening, with impairment in work and daily living abilities; b. reported or observed history of clear cognitive deterioration, with impairment in work and daily living abilities; c. history and examination confirming early and significant cognitive impairment: amnestic and non-amnestic symptoms). 2.Age between 50 and 80 years old (inclusive), with patients under 65 years old requiring AD biomarker confirmation for diagnosis. 3.MMSE score = 10 points 4.No improvement in clinical symptoms after at least six months of drug therapy 5.No severe cardiac, hepatic, renal, or other systemic diseases. 6.Able to cooperate with all examinations and surgeries required for the study. 7.Voluntarily participating in this study and signing the informed consent form.
Exclusion criteria
Exclusion criteria: Surgical contraindications, such as coagulation disorders (platelet count 100×109/L, INR > 1.4); Severe cardiopulmonary diseases and other surgical contraindications. For example, severe liver dysfunction with ALT or AST 3 times the upper limit of normal. Severe renal insufficiency with glomerular filtration rate less than 30ml/min/1.73m2. Severe mental illness that prevents cooperation with the study. History of intracranial hemorrhage or craniocerebral trauma within the past year. History of internal bleeding, such as uncontrolled gastrointestinal, genitourinary, or respiratory tract bleeding; Myocardial infarction within the past 30 days; Current drug or alcohol abuse or dependence; Allergy to surgery-related medications, instruments, or contrast agents; Any disease in its terminal stage with an expected life expectancy of less than 180 days; Currently participating in other clinical trials (excluding: observational studies without intervention, natural history and/or epidemiological studies); Currently participating in other clinical trials (excluding: observational studies without intervention, natural history and/or epidemiological studies); Recent similar surgery or treatment; Other patients deemed unsuitable for inclusion upon evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADL; | — |
Secondary
| Measure | Time frame |
|---|---|
| MMSE;MoCA; | — |
Countries
China
Contacts
Public Contactrong hu
Department of Neurosurgery, First Affiliated Hospital of Army Medical University
Outcome results
None listed